S&P Futures
3,857.25 +9.00 (+0.23%) Dow Futures
31,087.00 +74.00 (+0.24%) Nasdaq Futures
11,921.75 +41.50 (+0.35%) Russell 2000 Futures
1,734.00 +5.40 (+0.31%) Crude Oil
98.04 -0.49 (-0.50%) Gold
1,739.20 +2.70 (+0.16%)
Cyclacel Pharmaceuticals, Inc. (CYCCP)
Chart Events
Performance Outlook
| Previous Close | 7.70 |
| Open | 6.77 |
| Bid | 0.00 x 1000 |
| Ask | 7.75 x 800 |
| Day's Range | 7.73 - 7.73 |
| 52 Week Range | 5.17 - 11.17 |
| Volume | |
| Avg. Volume | 68 |
| Market Cap | 12.873M |
| Beta (5Y Monthly) | 1.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.05 |
| Earnings Date | May 12, 2020 |
| Forward Dividend & Yield | 0.60 (8.86%) |
| Ex-Dividend Date | Oct 14, 2021 |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CYCCP
Related Research
- Cyclacel Pharmaceuticals, Inc.Technical Assessment: Bearish in the Intermediate-TermCommodities continue to get shellacked, Treasury yields across the curve are still falling, people are starting to suggest that the Federal Reserve won't have to tighten as much as many thought just a month or two ago, recession fears (or worries that we are already in one) are rising quickly, EPS season is almost upon us (with many believing 2022 numbers are far too high), crypto remains in the dumpster, and the horrendous invasion of Ukraine never ends.RatingFair ValueEconomic MoatyesterdayArgus Research
- Benzinga
Cyclacel To Test Higher Doses Of Fadraciclib In Solid Tumor Patients
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) is adding two dose levels in a protocol amendment to test higher doses of oral fadraciclib before determining the recommended Phase 2 dose anticipated in 2H of 2022, citing the absence of dose-limiting toxicities. Fifteen patients with advanced solid tumors and lymphomas were treated with oral fadraciclib at all five doses. In the first oral treatment cycle with fadraciclib, a cutaneous T cell lymphoma patient achieved partial response (PR). A patient
- GlobeNewswire
Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline
- Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors - - No Dose Limiting Toxicities Observed at All Dose Levels Enrolled to Date - - Demonstrated Evidence of Target Engagement for CDK2 and CDK9 - - Early Anticancer Activity, Including Partial Response and Stable Disease with Tumor Shrinkage,Observed in Patients with Endometrial Cancer, Pancreatic Cancer and T Cell Lymphoma - - R&D Day Planned for Fall 2022 - BERKELEY HEIGHTS, N.J., June 30, 2022 (GLOBE NEWSWIR
- GlobeNewswire
Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors
BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Kenneth M. Ferguson, Ph.D., to its Board of Directors. Dr. Ferguson was elected by and will represent the 6% Convertible Exchangeable Preferred stockholders. "We are very pleased to welcome Ken to our Board of Directors,” said Ch
